Novo Nordisk says it is investigating a cyber incident that it describes as a potential data breach affecting information from some clinical trials. The company reports that it has identified the issue and is working to determine the scope of any unauthorized access. Novo Nordisk says it is probing whether patient-related data was involved and is assessing what information, if any, may have been accessed or exposed.
According to the reports, the company has engaged relevant parties and is carrying out internal reviews as part of its response. Novo Nordisk has flagged that the matter relates to data from a subset of clinical trials, indicating that the impact may not extend to all research datasets. The company is also taking steps aimed at addressing the incident and strengthening protections.
The reports do not provide details on the cause of the intrusion, the identity of any attacker, or the full extent of compromised information. The investigation is ongoing, with Novo Nordisk continuing to evaluate findings and determine appropriate next actions.
